Nuchal translucency measurements in consecutive normal pregnancies. Is there a predisposition to increased levels?

Prenatal Diagnosis

Volumn 22, Issue 9, 2002, Pages 759-762

  Maymon, R ^a   Padoa, A ^b   Dreazen, E ^b   Herman, A ^b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Down syndrome screening; Nuchal translucency; Subsequent pregnancy

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST;

ADULT; DOWN SYNDROME; FEMALE; HUMANS; ISRAEL; MASS SCREENING; NECK; PARITY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ULTRASONOGRAPHY, PRENATAL;

MARTES PENNANTI;

EID: 0036736189     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.399     Document Type: Article

References (24)

1. Baumgarten A. 1986. Racial difference and biological significance of maternal serum alpha-fetoprotein. Lancet ii: 573.
2. Dar H, Merskamer R, Berdichevsky D, David M. 1996. Maternal serum markers levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels. Am J Med Genet 61: 154-157.
3. Degani S, Leibovitz Z, Shapiro I, Gonen R, Ohel G. 1997. Fetal pyelectasis in consecutive pregnancies: a possible genetic predisposition. Ultrasound Obstet Gynecol 10: 19-21.
4. Hafner E, Schuchter K, Philipp K. 1995. Screening for chromosomal abnormalities in an unselected population by fetal nuchal translucency. Ultrasound Obstet Gynecol 6: 330-333.
5. Herman A, Dreazen E, Samandarov A, Bukovsky Z, Weinraub Z, Maymon R. 2000. On-to-on versus on-to-out nuchal translucency measurements. Ultrasound Obstet Gynecol 15: 126-130.
6. Holding S, Cuckle H. 1994. Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy. (Letter). Prenat Diagn 14: 321-324.
7. Lam YH, Tang MHY, Lee CP, et al. 2001. The effect of fetal gender on nuchal translucency at 10-14 weeks of gestation. Prenat Diagn 21: 627-629.
8. Larsen SO, Christiansen M, Norgaard-Pedersen B. 1998. Inclusion of serum marker measurements from a previous pregnancy improves Down syndrome screening performance. Prenat Diagn 18: 607-612.
9. Maymon R, Jauniaux E, Cohen O, Dreazen E, Weinraub Z, Herman A. 2000. Pregnancy outcome and infant follow-up of fetuses with abnormally increased first trimester nuchal translucency. Hum Reprod 15: 2023-2027.
10. Nicolaides KH, Sebire NJ, Snijders RJM. 1999. The 11-14 Week Scan: The Diagnosis of Fetal Abnormalities. Parthenon: New York.
11. Pandya PP, Snijders RJM, Johnson SJ, de Lourdes Brizot MJ, Nicolaides KH. 1995. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 102: 957-962.
12. Rausch DN, Lambert-Messerlian GM, Canick JA. 2000. Participation in maternal serum screening following screen-positive results in a previous pregnancy. J Med Screen 7: 4-6.
13. Robinson HP, Fleming JEE. 1975. A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynecol 82: 702-710.
14. Snijders RJM, Noble PL, Sebire NJ, Souka A, Nicolaides KH. 1998. UK multicenter project on assessment of risk of trisomy 21 by maternal age and nuchal translucency thickness at 10-14 weeks of gestation. Lancet 352: 343-346.
15. Spencer K. 1997. Between-pregnancy biological variability of maternal serum alpha-fetoprotein and free β-hCG; implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 17: 39-48.
16. Spencer K. 2000a. Second-trimester prenatal screening for Down syndrome screening and relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 20: 652-656.
17. Spencer K. 2000b. The influence of fetal sex in screening for Down syndrome in the second trimester using AFP and free β-hCG. Prenat Diagn 20: 648-651.
18. Spencer K. 2001. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies. Prenat Diagn 21: 445-447.
19. Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH. 2000. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20: 673-675.
20. Spong CY, Ghidini A, Stanley-Christian H, Meck JM, Seydel FD, Pezzullo JC. 1999. Risk of abnormal triple screen for Down syndrome is significantly higher in patients with female fetuses. Prenat Diagn 19: 337-339.
21. Thilaganathan B, Slack A, Wathen NC. 1997. Effect of first-trimester screening nuchal translucency on second trimester maternal serum biochemistry screening for Down's syndrome. Ultrasound Obstet Gynecol 10: 261-264.
22. Wald NJ, Cuckle HS. 1981. Raised maternal serum alpha-fetoprotein levels in subsequent pregnancies. (Letter). Lancet i: 1103.
23. Wald N, Kennard A, Hackshow A, McGuire A. 1997. Antenatal screening for Down's syndrome. J. Med Screen 4: 181-246.
24. Wax JR, Lopes AM, Bemm PAA, Lever T, Talinfeld JD, Ingardin CJ. 2000. Unexplained elevated midtrimester maternal serum levels of alpha feto-protein, human chorionic gonadotropin, or low unconjugated estriol: Recurrence risk and association with adverse perinatal outcome. J Matern Fetal Med 9: 161-164.